Abstract | BACKGROUND: METHODS: We quantified the contribution of UGT1A1*28 and ART to hyperbilirubinemia by longitudinally modeling 1386 total bilirubin levels in 96 human immunodeficiency virus (HIV)-infected individuals during a median of 6 years. RESULTS: CONCLUSIONS: Genotyping for UGT1A1*28 before initiation of ART would identify HIV-infected individuals at risk for hyperbilirubinemia and decrease episodes of jaundice.
|
Authors | Margalida Rotger, Patrick Taffe, Gabriela Bleiber, Huldrych F Gunthard, Hansjakob Furrer, Pietro Vernazza, Henning Drechsler, Enos Bernasconi, Martin Rickenbach, Amalio Telenti, Swiss HIV Cohort Study |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 192
Issue 8
Pg. 1381-6
(Oct 15 2005)
ISSN: 0022-1899 [Print] United States |
PMID | 16170755
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- UGT1A1 enzyme
- Glucuronosyltransferase
|
Topics |
- Adult
- Antiretroviral Therapy, Highly Active
(adverse effects)
- Cohort Studies
- Female
- Gilbert Disease
(complications)
- Glucuronosyltransferase
(genetics)
- Humans
- Hyperbilirubinemia
(chemically induced, complications)
- Male
- Middle Aged
- Treatment Outcome
|